AstraZeneca first quarter sales flat, but beat forecasts
Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning posted first-quarter 2014 financials, revealed sales for the period of $6.42 billion, unchanged in actual terms by 3% higher at constant exchange rates, beating the expectations of $6.37 billion of analysts polled by Thomson Reuters.
Core operating profit fell 16% (-11% CER) to $1.95 billion, and earnings per share fell 17% to $1.17, just under analysts expectations of $1.20. On a reported basis, operating profit was down 40% at $836 million and EPS was $0.40, a fall of 51%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze